Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) is set to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.12. The business's quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.57) earnings per share. On average, analysts expect Xenon Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Xenon Pharmaceuticals Price Performance
NASDAQ XENE traded up $0.75 on Friday, reaching $43.75. The company had a trading volume of 252,214 shares, compared to its average volume of 398,815. The firm has a market capitalization of $3.30 billion, a PE ratio of -16.08 and a beta of 1.19. Xenon Pharmaceuticals has a 1 year low of $27.99 and a 1 year high of $50.99. The firm has a 50-day moving average of $43.31 and a 200-day moving average of $41.29.
Insider Activity at Xenon Pharmaceuticals
In related news, Director Steven Gannon sold 13,000 shares of the company's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $601,640.00. Following the sale, the director now directly owns 2,000 shares of the company's stock, valued at approximately $92,560. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Xenon Pharmaceuticals news, EVP Sherrington Robin sold 7,137 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total value of $330,300.36. Following the sale, the executive vice president now directly owns 8,398 shares of the company's stock, valued at $388,659.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steven Gannon sold 13,000 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total value of $601,640.00. Following the completion of the sale, the director now directly owns 2,000 shares in the company, valued at $92,560. The disclosure for this sale can be found here. Corporate insiders own 5.43% of the company's stock.
Analysts Set New Price Targets
XENE has been the subject of a number of analyst reports. Wedbush upped their price target on Xenon Pharmaceuticals from $46.00 to $51.00 and gave the stock an "outperform" rating in a report on Friday, March 1st. Needham & Company LLC restated a "buy" rating and issued a $62.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, April 12th. Royal Bank of Canada cut their target price on Xenon Pharmaceuticals from $56.00 to $55.00 and set an "outperform" rating on the stock in a research report on Friday, March 1st. Citigroup assumed coverage on Xenon Pharmaceuticals in a research report on Thursday, January 4th. They issued a "buy" rating and a $62.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 10th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Xenon Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $59.44.
View Our Latest Report on XENE
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Recommended Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
